Global artificial intelligence stocks tumbled on Monday, September 14, 2026, after prominent industry chief executive officers called for a deliberate slowdown in AI development due to escalating safety concerns. The selloff rippled across Wall Street, Europe, and Asia, dampening markets that have relied heavily on massive technology sector spending.
Industry Leaders Call for an AI Development Slowdown
Confidence across global technology markets shook over the weekend after top artificial intelligence executives urged the industry to tap the brakes on advancing model capabilities. Anthropic CEO Dario Amodei shared a lengthy essay on X on Saturday calling for a global slowdown to address mounting security and safety risks. Both OpenAI Chief Executive Officer Sam Altman and Elon Musk, who runs xAI, publicly stated they agree with Amodei’s warnings.
The warnings follow a series of unsettling events at leading AI labs. Earlier in September, Anthropic researcher Jacob Coxon resigned, warning that AI developers are gambling with our lives,
according to reporting by Reuters.
In six to 12 months, AI agents could be capable of taking over the entire internet potentially causing hundreds of billions of dollars in damage.
Dario Amodei, CEO of Anthropic
Global Stock Markets React to Technology Selloff
The safety appeals triggered an immediate retreat in tech equities worldwide. On Wall Street, the Nasdaq 100 slid 1.2% to a six-week low in early trading before paring some losses, while the Philadelphia semiconductor index dropped 5.2% according to market data. Heavyweights including Nvidia fell 3%, Advanced Micro Devices dropped 4.5%, and Micron Technology shed 5.4%.
Similar pressures hit international exchanges. Europe’s tech sector retreated 2.2% amid a 6% decline for ASML, and Asian markets saw steep retreats, including a more than 10% plunge for SoftBank in Tokyo alongside pullbacks for TSMC and SK Hynix as reported by Reuters. Citigroup’s team led by Stuart Kaiser warned clients that a potential slowdown in model development could crimp earnings-per-share revisions and weaken the primary pillar of the ongoing equity rally.
If this does lead to sort of a slowdown and a rethink of AI spending, that will have ramifications for the economy and some important sectors of the stock market, because essentially, we’ve been running hot based on AI spending.
Steve Sosnick, chief market analyst at Interactive Brokers
OpenAI Delays Initial Public Offering Plans
Amid the safety debate, OpenAI CEO Sam Altman announced that OpenAI will not proceed with an initial public offering this year, pointing to safety concerns. Altman’s alignment with the pause creates potential delays for early investors such as SoftBank Group, which suffered a 10.7% drop in Tokyo following the disclosures.
While tech sector shares stumbled, broader indices found temporary insulation. Consequently, the S&P 500 limited its losses to a modest 0.3%.
Political Divisions and Macroeconomic Headwinds
The friction between commercial momentum and safety guardrails has also surfaced in Washington policy debates. U.S.
President Donald Trump dismissed the industry anxieties on his social media network, characterizing concerns as a sick conspiracy against AI and data centers. Trump argued that the United States must maintain its technological edge over global competitors like China rather than imposing internal brakes.
These technology sector deliberations coincide with broader cross-asset pressures.
- Saudi Arabia Vows Firm Response After Houthi Attacks
- Censys Debuts at GISEC Global 2026 for Internet Intelligence and Exposure Management
- Breakthrough Salk Study Uncovers Mechanism Behind Immunotherapy Resistance: Interferons, Mitochondrial Dysfunction, and PGE2″ Interferons, mitochondrial dysfunction and PGE2: Salk study reveals mechanism behind immunotherapy resistance. Boost its search engine visibility with relevant keywords for maximum impact. Immunotherapy resistance remains one of the biggest hurdles in cancer treatment. According to a recent study published in the journal Nature Communications, scientists at the Salk Institute have made a groundbreaking discovery that sheds light on the underlying mechanisms behind this resistance. The study reveals that interferons, a type of protein that plays a crucial role in the immune system, can contribute to mitochondrial dysfunction in cancer cells. This dysfunction can lead to the production of prostaglandin E2 (PGE2), a molecule that promotes tumor growth and resistance to immunotherapy. In their study, the researchers found that PGE2 production was a key factor in the development of immunotherapy resistance in cancer cells. The team used a combination of experimental and computational models to investigate the relationship between interferons, mitochondrial dysfunction, and PGE2 production. The findings of the study suggest that targeting PGE2 production could be a potential strategy for overcoming immunotherapy resistance. The researchers propose that blocking PGE2 receptors or inhibiting its production could help restore the function of mitochondria in cancer cells, making them more susceptible to immunotherapy. The study’s authors hope that their findings will pave the way for the development of new therapies that can overcome immunotherapy resistance and improve treatment outcomes for cancer patients. Key Takeaways: – Interferons contribute to mitochondrial dysfunction in cancer cells – Mitochondrial dysfunction leads to PGE2 production, promoting tumor growth and resistance to immunotherapy – Targeting PGE2 production could be a potential strategy for overcoming immunotherapy resistance – Restoring mitochondrial function in cancer cells could make them more susceptible to immunotherapy Keywords: immunotherapy resistance, interferons, mitochondrial dysfunction, PGE2, Salk Institute, cancer treatment, breakthrough study, Nature Communications. (archyworldys.com)